Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy ...

Roche RHHBY announced that the late-stage study evaluating the combination therapy of tiragolumab plus Tecentriq ...

For such a common disease, lung cancer can be hard to spot. In the early stages you probably won't even know you've got a ...

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved ...

Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led ...

For patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), standard use of the more accurate ...

Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, ...

One of the other presentations I'll just highlight is that one of our residents at Yale actually had a presentation yesterday ...

Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the ...

A new technology now being offered at Community Regional is helping doctors detect lung cancer far sooner than ever before.

Our findings show it's time to routinely adopt IMRT over 3D-CRT for lung cancer, just like we did for prostate, anal and brain tumors decades ago. The improved precision of IMRT translates into real ...

“The results from HERTHENA-Lung01 provide compelling evidence of efficacy of patritumab deruxtecan in heavily pretreated ...